Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms
CONCLUSION: Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.PMID:38626310 | DOI:10.1080/14740338.2024.2343015 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - April 16, 2024 Category: Drugs & Pharmacology Authors: Dipika Bansal Beema T Yoosuf Muhammed Favas Kt Pinaki Dutta Source Type: research

A cross talk study on sitagliptin mediated reclamation on TGF β signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet
In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.PMID:38604038 | DOI:10.1016/j.tice.2024.102375 (Source: Tissue and Cell)
Source: Tissue and Cell - April 11, 2024 Category: Cytology Authors: Dipti Nanda Anuradha Carani Venkatraman Kalpana Kalaivanan Source Type: research

A cross talk study on sitagliptin mediated reclamation on TGF β signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet
In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.PMID:38604038 | DOI:10.1016/j.tice.2024.102375 (Source: Tissue and Cell)
Source: Tissue and Cell - April 11, 2024 Category: Cytology Authors: Dipti Nanda Anuradha Carani Venkatraman Kalpana Kalaivanan Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research

The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform heal... (Source: Health Economics Review)
Source: Health Economics Review - April 2, 2024 Category: Health Management Authors: Shuyan Gu, Jinghong Gu, Xiaoyong Wang, Xiaoling Wang, Lu Li, Hai Gu and Biao Xu Tags: Research Source Type: research

The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
ConclusionOnce-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China. (Source: Health Economics Review)
Source: Health Economics Review - April 2, 2024 Category: International Medicine & Public Health Source Type: research

DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson ’s disease
In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD. (Source: AGE)
Source: AGE - April 2, 2024 Category: Geriatrics Source Type: research

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
J Inflamm Res. 2024 Mar 23;17:1897-1917. doi: 10.2147/JIR.S442106. eCollection 2024.ABSTRACTDPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augment...
Source: Cell Research - March 28, 2024 Category: Cytology Authors: Kashif Rahim Muhammad Shan Ihtisham Ul Haq Muhammad Naveed Nawaz Sajida Maryam Mansour S Alturki Abdulaziz H Al Khzem Kamel Metwally Simona Cavalu Saleh F Alqifari Galal Yahya Source Type: research